Related Experiment Videos
[Penetration of mezlocillin into bronchial secretions (author's transl)]
Abstract:
The penetration of mezlocillin into bronchial secretions collected by fiberoscopy was determined in 18 hospital patients with acute-on-chronic bronchial infection. Samples of blood and bronchial mucus were collected simultaneously 3 hours after each 12-hourly intramuscular injection of 1 g mezlocillin. Antibiotic concentrations were measured by the microbiological method. Mezlocillin concentrations in bronchial secretions averaged 50 % of concomitant serum concentrations. The rate of penetration of the drug was higher than that observed with ampicillin in similar conditions. The mean bronchial level of 3 micrograms/ml was indicative of a high therapeutic index in relation to the MICs of the pathogens isolated in these patients. It is concluded that intramuscular mezlocillin is indicated for the treatment of acute exacerbations of chronic bronchial infections due to highly sensitive organisms.
Insights
Mezlocillin effectively penetrates bronchial secretions, reaching concentrations 50% of serum levels in patients with chronic bronchial infections. This antibiotic demonstrates higher penetration than ampicillin, supporting its use for treating sensitive bacterial exacerbations.
Area of Science:
- Pharmacology
- Respiratory Medicine
- Infectious Diseases
Context:
- Assessing antibiotic efficacy in respiratory tract infections.
- Evaluating drug penetration into lung tissues is crucial for treatment success.
- Acute-on-chronic bronchial infections present challenges in achieving therapeutic drug levels.
Purpose:
- To quantify mezlocillin penetration into bronchial secretions.
- To compare mezlocillin's penetration rate with ampicillin.
- To determine the therapeutic potential of mezlocillin in bronchial infections.
Summary:
- Mezlocillin administered intramuscularly achieved concentrations in bronchial secretions that were 50% of concurrent serum levels.
- The drug's penetration rate into bronchial secretions exceeded that of ampicillin under similar conditions.
- A mean bronchial concentration of 3 µg/ml suggests a favorable therapeutic index against common respiratory pathogens.
Impact:
- Intramuscular mezlocillin demonstrates significant penetration into bronchial secretions.
- The findings support mezlocillin as a viable treatment option for acute exacerbations of chronic bronchial infections.
- Results indicate mezlocillin's potential for effective management of infections caused by highly sensitive organisms.